Form 4: SCPH Director's Options Converted in Merger

scPharmaceuticals Director Mette Kirstine Agger's stock options were cancelled and converted into cash and Contingent Value Rights following the completion of a tender offer by MannKind Corporation.

Summary

• Reporting Person Mette Kirstine Agger, a Director of scPharmaceuticals Inc., reported changes in beneficial ownership.
• The changes are a result of the completion of a tender offer by Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of MannKind Corporation, for shares of scPharmaceuticals Inc. common stock on October 7, 2025.
• This tender offer was made pursuant to an Agreement and Plan of Merger dated August 24, 2025.
• Immediately prior to the merger's effective time, all outstanding and unexercised stock options with an exercise price less than $5.35 were cancelled.
• Option holders received cash equal to the total number of shares subject to the option multiplied by the difference between the merger price of $5.35 and the option's exercise price.
• Additionally, option holders received one Contingent Value Right (CVR) for each share subject to such option.
• Agger's 30,000 stock options with an exercise price of $3.85 and 19,750 stock options with an exercise price of $4.11 were subject to this conversion.

Sentiment

Score: 6

Explanation: The filing reports a completed corporate action (merger) which is a definitive event. For option holders, it represents a realization of value (cash) and potential future value (CVRs). While the CVRs introduce uncertainty, the overall event is a positive liquidity event for those holding in-the-money options.

Positives

• Director's stock options were successfully converted into cash and Contingent Value Rights as part of the merger, providing liquidity and potential future value.
• The merger consideration of $5.35 per share for options with lower exercise prices indicates a premium over the exercise price for option holders.

Negatives

• The cancellation of stock options means the director no longer holds direct equity options in scPharmaceuticals Inc.
• The value of the Contingent Value Rights is uncertain and dependent on future events.

Risks

• The value of the Contingent Value Rights (CVRs) is subject to future performance or milestones, which may not be achieved, potentially resulting in no additional payout.

Future Outlook

The future outlook for former scPharmaceuticals Inc. option holders includes potential additional value from Contingent Value Rights, which are dependent on future events or milestones.

Industry Context

This filing reflects the final stages of a corporate acquisition within the pharmaceutical sector, where a larger entity (MannKind Corporation) acquires a smaller one (scPharmaceuticals Inc.). Such mergers are common for strategic growth, portfolio expansion, or to gain access to specific technologies or drug candidates. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech/pharma mergers to bridge valuation gaps and share risk related to future product development or regulatory milestones.

Comparison to Industry Standards

• The use of a tender offer followed by a merger is a standard acquisition mechanism in the U.S. market, particularly for public companies.
• The inclusion of Contingent Value Rights (CVRs) in merger agreements is a common practice in the biotechnology and pharmaceutical industries, often seen in deals involving larger pharmaceutical companies acquiring smaller biotechs, to provide additional consideration tied to the achievement of specific clinical, regulatory, or commercial milestones for acquired assets.
• The conversion of in-the-money stock options into cash and CVRs at the merger price is a standard treatment for equity incentives during an acquisition, ensuring that option holders participate in the transaction's value.

Stakeholder Impact

• Shareholders (former option holders): Received cash and CVRs, realizing value from their options.
• Employees (if option holders): Similar to shareholders, received cash and CVRs for their options.

Next Steps

• Potential future payouts to CVR holders based on the achievement of specified milestones.

Key Dates

Keywords

scPharmaceuticals, SCPH, MannKind Corporation, Merger, Tender Offer, Stock Options, Form 4, Beneficial Ownership, Contingent Value Rights, CVR